Merrimack Announces U.S. FDA Approval of ONIVYDE™ (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. HOOD
8. DFTX
9. MU
10. IBM

Go back to Merrimack Announces U.S. FDA Approval of ONIVYDE™ (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer

Merrimack Pharmaceuticals (MACK) Weakness Creates Buying Opportunity, Mizuho Securities Says

October 23, 2015 6:51 AM EDT

Weakness in Merrimack Pharmaceuticals (NASDAQ: MACK) following FDA approval of ONIVYDE presents a buying opportunity, according to Eric Criscuolo of Mizuho Securities. The firm reiterated an Outperform rating and price target of $16.

Criscuolo commented, "We think the 13% decline following news of ONIVYDE approval... More

Merrimack (MACK) Onivyde Labeling Appears as Expected, Says Mizuho Securities

October 22, 2015 2:14 PM EDT

Mizuho Securities maintained a Buy rating on Merrimack Pharmaceuticals (NASDAQ: MACK) with a price target of $16. Shares dropped 20% after Merrimack announced FDA approval for MM-398. In the view of analyst Eric Criscuolo, the label was as expected, despite the Black Box warning for diarrhea and... More

Merrimack Pharma (MACK) Drops Lower Following ONIVYDE Approval; Will Include 'Boxed Warning'

October 22, 2015 2:10 PM EDT

Merrimack (Nasdaq: MACK) shares are down over 21 percent with heavy volume Thursday afternoon after the company... More